Greenland Mines Ltd. (NASDAQ: GRML) announced that Innovation, Science and Economic Development Canada has granted a patent covering technology exclusively licensed by the company for Klotho-based gene therapies targeting cognition, memory and neurodegenerative diseases. The patent protects the use of the secreted Klotho ("s-KL") RNA splice variant in genetic therapies and includes 42 claims covering its synthesis, delivery methods and potential application across multiple neurological disorders, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis ("ALS") and multiple sclerosis.
The company said the Canadian patent expands its intellectual property portfolio for Klotho-based therapeutics and complements previously issued patents in the United States, China and Europe. This development is significant because it strengthens Greenland Mines' position in the competitive field of neurodegenerative disease treatments, offering a novel approach that targets the underlying mechanisms of these debilitating conditions. The Klotho gene has been associated with longevity and cognitive function, and its upregulation may provide therapeutic benefits for patients suffering from memory loss and motor neuron degeneration.
Greenland Mines added that process development and manufacturing for lead candidate KLTO-101 is scheduled to begin in August 2026, while KLTO-202 has advanced to GMP manufacturing as the company prepares for regulatory interactions later this year. The advancement of these candidates into manufacturing stages indicates progress toward clinical trials and potential commercialization. The company's strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
For investors, the patent grant enhances the company's intellectual property moat and could pave the way for partnerships or licensing deals. The focus on ALS with KLTO-202 is particularly noteworthy given the high unmet medical need in this area. The company plans to engage with regulatory authorities later this year, which could provide clarity on the clinical pathway for its lead candidates. The full press release is available at https://ibn.fm/x2pHA.
